{
    "symbol": "MCK",
    "quarter": 1,
    "year": 2023,
    "date": "2022-08-03 20:30:26",
    "content": " As a result of our first quarter performance and McKesson's continued role in the COVID-19 response efforts, we are raising our guidance range for fiscal 2023 adjusted earnings per diluted share from $22.90 to $23.60 to a new range of $23.95 to $24.65, successful execution against our company's priorities, priorities of people and culture, sustainable core growth, streamlining the portfolio and expanding the oncology and biopharma services ecosystems are really what underpin our fiscal 2023 outlook and our long-term growth framework."
}